0
E-MAIL THIS PAGE  |  PRINT THIS PAGE
Information for Healthcare Professionals
References

1. Wright CE. Clinical pharmacokinetics of alprazolam extended release: a summary. Curr Ther Res. 1995;56:947-956.

2. Klein E. The role of extended-release benzodiazepines in the treatment of anxiety: a risk-benefit evaluation with a focus on extended-release alprazolam. J Clin Psychiatry. 2002;63(suppl 14):27-33.

3. Harnett-Sheehan KH. Speed of onset of clinical benefit of Alprazolam-XR compared to Alprazolam-CT in panic disorder. Poster presented at: Annual Meeting of the International Forum on Mood and Anxiety Disorders; November 19, 2003; Monaco.

4. Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry. 1993;150:1210-1215.

5. Data on file. Pfizer Inc., New York, NY.

6. Pecknold J, Luthe L, Munjack D, Alexander P. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol. 1994;14:314-321.

7. Ciraulo DA, Sand-Segal O. Sedative-, hypnotic-, or anxiolytic-related abuse. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock’s Comprehensive Textbook of Psychiatry. Vol 1. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:1071-2085.

8. Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2002;63(suppl 14):9-16.

Important Safety Information: XANAX XR is contraindicated in patients with known sensitivity to this drug or other benzodiazepines, in patients with acute narrow-angle glaucoma, and in patients taking potent CYP3A inhibitors, such as ketoconazole and itraconazole.

Certain adverse clinical events are a direct consequence of physical dependence to alprazolam. These include a spectrum of discontinuation symptoms, the most important being the possibility of seizure.

The most commonly observed adverse events in patients treated with XANAX XR in controlled clinical trials (≥5% and at least twice the incidence observed for placebo) were: sedation (45.2% vs 22.6%), somnolence (23.0% vs 6.0%), memory impairment (15.4% vs 6.9%), dysarthria (10.9% vs 2.6%), abnormal coordination (9.4% vs 0.9%), ataxia (7.2% vs 3.2%), and decreased libido (6.0% vs 2.3%).

Please see full prescribing information for more information.


Privacy Policy    Terms of Use    Contact Pfizer

XN141121B © 2006 Pfizer Inc. All rights reserved.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.